Johnson Johnson will buy private developer & of medicines for $ $1,75 bi

(Reuters)-the Johnson Johnson said & who will purchase the private developer of medicines Alios BioPharma for 1.75 billion dollars in cash to gain access to a portfolio of drugs that fight viral infections.
Johnson Johnson & said the agreement includes the experimental drug from Alios for children with respiratory syncytial virus.
In the United States, respiratory syncytial virus is the most common cause of inflammation in the small Airways of the lungs and pneumonia in children under 1 year, according to the Center for disease control and prevention in the United States.
(For Vidya L Nathan)